Financial Performance - The company's revenue for Q3 2023 was ¥315,750,993.99, representing a decrease of 1.34% compared to the same period last year[3]. - Net profit attributable to shareholders for Q3 2023 was ¥4,773,724.67, down 3.27% year-on-year, while the net profit excluding non-recurring items increased by 11.24% to ¥3,132,788.39[3]. - Basic earnings per share for Q3 2023 were ¥0.0049, a decrease of 3.92% year-on-year, while diluted earnings per share remained the same[3]. - Total operating revenue for the period reached CNY 1,044,242,077.32, an increase of 3.3% compared to CNY 1,013,753,250.35 in the previous period[14]. - Net profit for the period was CNY 14,851,915.32, compared to CNY 11,726,341.24 in the previous period, representing an increase of 26.5%[15]. - Earnings per share (EPS) for the period was CNY 0.0161, up from CNY 0.0129 in the previous period[16]. Assets and Liabilities - Total assets at the end of Q3 2023 were ¥4,466,267,721.29, a decrease of 4.67% from the end of the previous year[3]. - The company's total current assets decreased from 1,238,370,787.12 to 1,049,016,294.36, a decline of approximately 15.3%[12]. - Cash and cash equivalents decreased from 336,821,630.18 to 181,006,983.27, representing a drop of about 46.3%[11]. - The total assets of the company decreased from 4,685,114,987.39 to 4,466,267,721.29, a reduction of approximately 4.7%[12]. - The company's total liabilities increased from 671,861,996.48 to 511,997,301.67, indicating a decrease of about 24.3%[12]. - The total liabilities decreased to CNY 2,148,434,563.34 from CNY 2,316,613,744.76, a reduction of 7.2%[15]. Cash Flow - The company's cash flow from operating activities for the year-to-date was ¥85,035,967.09, reflecting a decline of 4.11% compared to the same period last year[3]. - Cash flow from operating activities totaled CNY 1,052,761,627.96, a decrease from CNY 1,074,408,967.19 in the previous period[17]. - The net cash flow from operating activities was $85,035,967.09, a decrease from $88,676,122.92 in the previous period, reflecting a decline of approximately 1.85%[18]. - The net cash flow from investing activities was $83,292,448.53, a significant improvement compared to a negative cash flow of -$15,353,252.35 in the previous period[18]. - Cash inflow from financing activities totaled $130,000,000.00, down from $1,607,000,000.00 in the previous period, indicating a decrease of approximately 91.88%[18]. - The total cash outflow from financing activities was $355,612,747.34, compared to $1,708,327,368.30 in the previous period, showing a reduction of about 79.16%[18]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 66,592, with the largest shareholder holding 19.66% of shares[7]. - The number of shares held by the top ten shareholders includes 190,000,000 shares from the largest shareholder, indicating a concentrated ownership structure[7]. - The company has pledged shares totaling 150,000,000, indicating potential liquidity concerns among major shareholders[7]. Research and Development - The company is closely monitoring the Phase III clinical trial results of its new drug, which has recently unblinded[10]. - Research and development expenses increased to CNY 29,740,704.07 from CNY 24,238,112.30, marking a rise of 22.8%[14]. Other Financial Metrics - The weighted average return on equity was 0.20%, a slight decrease of 0.01% compared to the previous year[3]. - The company reported a significant increase in long-term deferred expenses by 78.35% due to workshop renovation costs[5]. - Investment income for the year-to-date increased by 117.93% compared to the same period last year, indicating growth in investment returns[6]. - The total non-recurring gains and losses for Q3 2023 amounted to ¥1,640,936.28, with government subsidies contributing significantly to this figure[4]. - Financial expenses for the period were CNY 57,742,257.87, slightly up from CNY 57,056,147.81 in the previous period[15]. - Deferred income decreased to CNY 66,597,240.88 from CNY 71,825,767.12, a decline of 7.2%[15]. - Total equity attributable to shareholders of the parent company was CNY 2,317,359,851.64, down from CNY 2,336,859,413.77, a decrease of 0.8%[15]. Audit and Accounting Standards - The company did not undergo an audit for the third quarter report, which was released on October 26, 2023[19]. - The company is implementing new accounting standards starting in 2023, which may affect financial reporting[19].

证券代码：000766 证券简称：通化金马 公告编号：2023-52 通化金马药业集团股份有限公司 第十一届董事会第三次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 1.通化金马药业集团股份有限公司第十一届董事会第三次会议通知于 2023 年 10 月 17 日以微信、电子邮件形式送达全体董事。 公司 2023 年第三季度报告同日披露于巨潮资讯网。 会议以 9 票赞同，0 票反对，0 票弃权，审议通过了公司 2023 年第三季度报 告。 三、备查文件 经与会董事签字并加盖董事会印章的董事会决议。 通化金马药业集团股份有限公司董事会 2. 2023 年 10 月 26 日上午 9 时以现场和通讯方式召开。 3.会议应到董事 9 人，实到董事 9 人。 4.会议由董事长张玉富先生主持。监事会成员及部分高管人员列席了本次会 议。 5.本次董事会会议的召开符合有关法律、行政法规、部门规章、规范性文件 和公司章程的规定。 二、董事会会议审议情况 审议公司 2023 年第三季度报告。 2023 年 10 月 26 日 ...

3.会议应到监事 3 人，实到监事 3 人。 证券代码：000766 证券简称：通化金马 公告编号：2023-53 通化金马药业集团股份有限公司 第十一届监事会第三次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 1.通化金马药业集团股份有限公司第十一届监事会第三次会议通知于 2023 年 10 月 17 日以微信形式送达全体监事。 2. 2023 年 10 月 26 日上午 10 时以现场和通讯方式召开。 4.会议由监事会主席许长有主持。 5.本次监事会会议的召开符合有关法律、行政法规、部门规章、规范性文件 和公司章程的规定。 二、监事会会议审议情况 审议公司 2023 年第三季度报告 监事会的专项审核意见：经审核，监事会认为董事会编制和审议公司 2023 年第三季度报告的程序符合法律、行政法规及中国证监会的规定，报告内容真实、 准确、完整地反映了上市公司的实际情况，不存在任何虚假记载、误导性陈述或 者重大遗漏。 公司 2023 年第三季度报告同日披露于巨潮资讯网。 会议以 3 票赞同，0 票反对，0 票弃权，审议通过了 ...

证券代码：000766 证券简称：通化金马 公告编号：2023-51 通化金马药业集团股份有限公司 股票交易异常波动公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、通化金马药业集团股份有限公司（以下简称"公司"）股票交易价格连续 二个交易日（2023 年 10 月 12 日、10 月 13 日）日收盘价格涨幅偏离值累计超过 20%。根据深圳证券交易所的有关规定，该情形属于股票交易异常波动的情况。 2、目前公司经营情况及内外部经营环境未发生重大变化。公司郑重提醒广 大投资者，股票价格可能受到宏观经济、市场环境、行业发展、公司经营情况及 投资者偏好等多重因素影响，敬请广大投资者注意交易风险，审慎决策、理性投 资。 1、公司前期披露的信息未发现需要更正、补充之处。 2、公司未发现近期公共传媒报道可能或已经对公司股票交易价格产生较大 影响的未公开重大信息。 3、目前公司经营情况及内外部经营环境未发生重大变化。 3、新药研发，尤其是国家 1 类新药研发，受到技术、审批、政策等多方面 因素的影响，相关研发进展及未来产品市场竞争形势等均存在诸多不确定性 ...

证券代码：000766 证券简称：通化金马 公告编号：2023-49 通化金马药业集团股份有限公司 股票交易异常波动公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、通化金马药业集团股份有限公司（以下简称"公司"）股票交易价格连续 二个交易日（2023 年 9 月 22 日、9 月 25 日）日收盘价格跌幅偏离值累计超过 20%。根据深圳证券交易所的有关规定，该情形属于股票交易异常波动的情况。 2、目前公司经营情况及内外部经营环境未发生重大变化。公司郑重提醒广 大投资者，股票价格可能受到宏观经济、市场环境、行业发展、公司经营情况及 投资者偏好等多重因素影响，敬请广大投资者注意交易风险，审慎决策、理性投 资。 公司股票交易价格连续二个交易日（2023 年 9 月 22 日、9 月 25 日）日收盘 价格跌幅偏离值累计超过 20%。根据深圳证券交易所的有关规定，该情形属于股 票交易异常波动的情况。 二、公司关注并核实的相关情况 针对公司股票异常波动，经通过电话、现场问询等方式对公司控股股东、实 际控制人、董事会、管理层进行核实，现对有关核实情况 ...

证券代码：000766 证券简称：通化金马 公告编号：2023-48 通化金马药业集团股份有限公司 关于国家 1.1 类化学药琥珀八氢氨吖啶片 III 期临床试验揭盲结果的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、新药研发尤其是国家 1.1 类新药的研发受到技术、审批、政策等多方面 因素的影响，药政评审决策、相关研发进展及未来产品市场竞争形势等均存在不 确定性风险，敬请广大投资者注意投资风险。 2、目前公司经营情况及内外部经营环境未发生重大变化。本次揭盲结果不 会对公司当前业绩产生重大影响。 近日，通化金马药业集团股份有限公司（以下简称"公司"）全资子公司长 春华洋高科技有限公司（以下简称"长春华洋"）自主研发的琥珀八氢氨吖啶片 项目（以下简称"该项目"）取得重大研究进展。该项目经过双盲、双模拟、随 机、安慰剂/阳性平行对照Ⅲ期临床试验，日前已完成Ⅲ期揭盲和主要数据的统 计分析。现将就本研究项目的相关信息进行公告如下： 一、项目背景 该项目研发新药用于治疗轻、中度阿尔茨海默病。根据国家政策要求：《"健 康中国2030"规划纲要》提出 ...

证券代码：000766 证券简称：通化金马 公告编号：2023-47 通化金马药业集团股份有限公司 股票交易异常波动公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、通化金马药业集团股份有限公司（以下简称"公司"）股票交易价格连续 二个交易日（2023 年 9 月 13 日、9 月 14 日）日收盘价格涨幅偏离值累计超过 20%。根据深圳证券交易所的有关规定，该情形属于股票交易异常波动的情况。 2、目前公司经营情况及内外部经营环境未发生重大变化。公司郑重提醒广 大投资者，股票价格可能受到宏观经济、市场环境、行业发展、公司经营情况及 投资者偏好等多重因素影响，敬请广大投资者注意交易风险，审慎决策、理性投 资。 3、2023 年 8 月 31 日，公司披露了《关于完成国家 I.I 类新药琥珀八氢氨 吖啶片 III 期临床试验盲态数据审核的公告》，集团公司及全资子公司长春华洋 高科技有限公司自主研发、具有独家专利的琥珀八氢氨吖啶片已经完成 III 期临 床成盲态数据审核。但新药研发尤其是国家 I.I 类新药的研发受到技术、审批、 政策等多方面因素 ...

证券代码：000766 证券简称：通化金马 公告编号：2023-46 通化金马药业集团股份有限公司 股票交易异常波动公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、股票交易异常波动情况 通化金马药业集团股份有限公司（以下简称"公司"）股票交易价格连续二 个交易日（2023 年 9 月 11 日、9 月 12 日）日收盘价格涨幅偏离值累计超过 20%。 根据深圳证券交易所的有关规定，该情形属于股票交易异常波动的情况。 二、公司关注并核实的相关情况 针对公司股票异常波动，经通过电话、现场问询等方式对公司控股股东、实 际控制人、董事会、管理层进行核实，现对有关核实情况说明如下： 1、公司前期披露的信息未发现需要更正、补充之处。 2、公司未发现近期公共传媒报道可能或已经对公司股票交易价格产生较大 影响的未公开重大信息。 3、目前公司经营情况及内外部经营环境未发生重大变化。 4、2023 年 8 月 31 日，公司披露了《关于完成国家 I.I 类新药琥珀八氢氨 吖啶片 III 期临床试验盲态数据审核的公告》，集团公司及全资子公司长春华洋 高科技有限公司自主研发 ...

证券代码：000766 证券简称：通化金马 公告编号：2023-45 通化金马药业集团股份有限公司 股票交易异常波动公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、股票交易异常波动情况 通化金马药业集团股份有限公司（以下简称"公司"）股票交易价格连续二 个交易日（2023 年 8 月 30 日、8 月 31 日）日收盘价格涨幅偏离值累计超过 20%。 根据深圳证券交易所的有关规定，该情形属于股票交易异常波动的情况。 二、公司关注并核实的相关情况 针对公司股票异常波动，经通过电话、现场问询等方式对公司控股股东、实 际控制人、董事会、管理层进行核实，现对有关核实情况说明如下： 1、公司前期披露的信息未发现需要更正、补充之处。 2、公司未发现近期公共传媒报道可能或已经对公司股票交易价格产生较大 影响的未公开重大信息。 3、目前公司经营情况及内外部经营环境未发生重大变化。 4、2023 年 8 月 31 日，公司披露了《关于完成国家 I.I 类新药琥珀八氢氨 吖啶片 III 期临床试验盲态数据审核的公告》，集团公司及全资子公司长春华洋 高科技有限公司自主研发 ...

Financial Performance - The company's operating revenue for the first half of 2023 was ¥728,491,083.33, representing a 5.01% increase compared to ¥693,725,150.23 in the same period last year[11]. - Net profit attributable to shareholders was ¥10,776,911.31, a significant increase of 43.12% from ¥7,529,859.90 in the previous year[11]. - The net profit after deducting non-recurring gains and losses reached ¥7,709,212.42, which is a 107.07% increase compared to ¥3,722,972.58 in the same period last year[11]. - The basic earnings per share rose to ¥0.0112, up 43.59% from ¥0.0078 in the previous year[11]. - The total operating revenue for the first half of 2023 reached CNY 728,491,083.33, an increase of 5.7% compared to CNY 693,725,150.23 in the same period of 2022[89]. - Total operating costs amounted to CNY 710,963,901.65, up from CNY 684,018,066.24, reflecting a year-on-year increase of 3.9%[90]. - Net profit for the first half of 2023 was CNY 10,304,366.03, compared to CNY 7,076,237.91 in the previous year, indicating a significant improvement[90]. - The total comprehensive income for the first half of 2023 was CNY 10,304,366.03, compared to CNY 7,076,237.91 in the first half of 2022, marking an increase of around 45%[91]. Assets and Liabilities - The total assets at the end of the reporting period were ¥4,534,138,987.01, a decrease of 3.22% from ¥4,685,114,987.39 at the end of the previous year[11]. - The company's total liabilities decreased to CNY 2,155,333,378.35 from CNY 2,316,613,744.76, a reduction of about 7%[87]. - Cash and cash equivalents decreased to ¥229,111,387.06, making up 5.05% of total assets, down from 7.19% the previous year[29]. - Accounts receivable increased to ¥436,538,415.65, representing 9.63% of total assets, up from 9.05% year-over-year[29]. - Inventory stood at ¥378,219,837.23, accounting for 8.34% of total assets, slightly up from 8.14%[29]. - The company's total liabilities at the end of the reporting period were 1,000,000,000.00 CNY, reflecting a stable financial position[104]. Cash Flow - The net cash flow from operating activities decreased by 29.25% to ¥41,102,119.70 from ¥58,097,322.65 in the same period last year[11]. - The company's cash flow from operating activities for the first half of 2023 was approximately ¥890,090, compared to ¥39,493,373 in the same period of 2022, indicating a significant decrease[97]. - The total cash outflow for operating activities was ¥425,916,612, compared to ¥325,234,992 in the first half of 2022, indicating an increase of approximately 30.9%[97]. - The net cash flow from investment activities was ¥95,211,614, a recovery from a negative cash flow of ¥6,292,861 in the first half of 2022[98]. Research and Development - The company’s R&D investment increased by 17.50% to ¥25,093,147.80 from ¥21,355,042.90 in the previous year, indicating a strong commitment to new drug development[24]. - Research and development expenses increased to CNY 21,717,792.04, up from CNY 18,946,335.68, marking a rise of 14.7%[90]. - The company is actively engaged in new product development and technological innovation to enhance product competitiveness[19]. Market and Industry - The pharmaceutical industry in China is expected to continue growing due to increasing health awareness and an aging population[16]. - The government is implementing policies to support the development of traditional Chinese medicine, which presents new opportunities for the company[16]. - The company operates in various therapeutic areas, including oncology, cardiovascular, and digestive systems, with leading products such as compound Lactobacillus tablets and rheumatism pain relief capsules[16]. Environmental Compliance - The company has established a quality management system to ensure compliance with GMP standards, controlling quality across all production stages[42]. - The company is classified as a key pollutant discharge unit and adheres to strict environmental regulations and industry standards[47]. - The company reported a stable operation of its wastewater treatment facility, processing a total of 139,622 tons of wastewater in the first half of 2023, with a COD average effluent concentration of 16.95 mg/L and ammonia nitrogen average effluent concentration of 0.139 mg/L[51]. - The company invested 8.2 million yuan in 2016 to expand its wastewater treatment capacity to 1,000 tons per year, which was completed and put into operation in August 2018[51]. Shareholder Information - The company reported a total of 966,494,707 shares outstanding, with 12.20% being limited sale condition shares and 87.80% being unrestricted sale condition shares[70]. - The largest shareholder, Yu Lanjun, holds 190,000,000 shares, representing 19.66% of the total shares, with 150,000,000 shares pledged[72]. - The company has not reported any changes in accounting policies or prior period error corrections for this reporting period[107]. Risks and Challenges - The company faces various risks as outlined in the report, and investors are advised to read the relevant sections carefully[2]. - The company faces risks from pharmaceutical industry policies, which may impact sales volume and pricing due to reforms in drug approval and procurement policies[41]. - New product development is a high-risk area, with long cycles and uncertainties affecting market prospects and economic returns[42]. Corporate Governance - The company has not engaged in any major related party transactions during the reporting period[59]. - The company has not provided any guarantees to related parties during the reporting period[64]. - The company did not undergo any changes in its controlling shareholder or actual controller during the reporting period[81].